BI Asset Management Fondsmaeglerselskab A S Has $2.06 Million Stock Position in Natera, Inc. $NTRA

BI Asset Management Fondsmaeglerselskab A S grew its holdings in Natera, Inc. (NASDAQ:NTRA) by 333.7% in the first quarter, HoldingsChannel reports. The fund owned 10,296 shares of the medical research company’s stock after buying an additional 7,922 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Natera were worth $2,059,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of NTRA. Robinhood Asset Management LLC acquired a new position in shares of Natera during the 4th quarter worth approximately $12,981,000. Systrade AG acquired a new stake in shares of Natera in the fourth quarter valued at approximately $11,454,000. Quantbot Technologies LP acquired a new stake in shares of Natera in the third quarter valued at approximately $1,069,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of Natera by 5.7% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 159,166 shares of the medical research company’s stock valued at $25,621,000 after buying an additional 8,630 shares during the period. Finally, J. Safra Sarasin Holding AG bought a new stake in shares of Natera in the fourth quarter valued at approximately $2,825,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. The Goldman Sachs Group started coverage on Natera in a research report on Friday, June 5th. They set a “neutral” rating and a $245.00 price target on the stock. William Blair started coverage on Natera in a research report on Tuesday, April 14th. They set an “outperform” rating for the company. Robert W. Baird set a $265.00 target price on Natera in a report on Friday, May 8th. Morgan Stanley reduced their target price on Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a report on Tuesday, March 3rd. Finally, Wall Street Zen cut Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $257.71.

Natera Stock Performance

Shares of NTRA stock opened at $234.76 on Wednesday. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36. The stock’s fifty day moving average price is $209.55 and its two-hundred day moving average price is $215.30. The company has a market cap of $33.62 billion, a PE ratio of -144.02 and a beta of 1.56.

Insider Buying and Selling at Natera

In related news, Director Gail Boxer Marcus sold 11,000 shares of the firm’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $217.21, for a total value of $2,389,310.00. Following the sale, the director directly owned 6,183 shares of the company’s stock, valued at $1,343,009.43. This trade represents a 64.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Roelof Botha sold 78,000 shares of Natera stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $220.31, for a total value of $17,184,180.00. Following the completion of the transaction, the director owned 1,076,198 shares in the company, valued at approximately $237,097,181.38. This represents a 6.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 162,342 shares of company stock worth $35,283,396 over the last quarter. 5.05% of the stock is currently owned by company insiders.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.